View Financial HealthGNI Group 배당 및 자사주 매입배당 기준 점검 0/6GNI Group 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-7.7%자사주 매입 수익률총 주주 수익률-7.7%미래 배당 수익률0.6%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 13GNI Group Ltd., Annual General Meeting, Mar 26, 2026GNI Group Ltd., Annual General Meeting, Mar 26, 2026.공시 • Jan 23+ 1 more updateGNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2025GNI Group Ltd. revised consolidated earnings guidance for the fiscal year ending December 31, 2025. For the year, the group now expects Revenue of JPY 26,841 million against previous guidance of JPY 28,733 million, operating loss of JPY 2,725 million against previous guidance of operating profit of JPY 23,217 million, Loss Before Income Taxes of JPY 3,795 million against previous guidance of Profit Before Income Taxes of JPY 22,541 million, Loss attributable to the owners of parent of JPY 3,420 million against previous guidance of profit Attributable to Owners of the Parent of JPY 12,058 million, basic loss per share of JPY 65.18 against previous guidance of basic earnings per share of JPY 240.42. Reasons for Revision: Revenue has been revised primarily due to the pharmaceutical business, as Etorel® (nintedanib), which was launched in 2025, is now expected to fall below the initial budget. Meanwhile, in the pharmaceutical business as a whole, sales of the Company's core product, ETUARY®, continue to perform steadily, and revenue is expected to reach a record high for the 12th consecutive fiscal year since its launch in 2014. In addition, in the Medtech business, following the acquisition of Berkeley Advanced Biomaterials (BAB) in 2017, revenue is expected to reach record highs for the 9th consecutive fiscal year. As a result, consolidated revenue is expected to increase by JPY 3,230 million compared to the previous fiscal year, to JPY 26,841 million. Profit: Deferral of the listing of consolidated subsidiary Cullgen. In the Group's pharmaceutical (Biotech) business, Cullgen Inc. ("Cullgen"), a core subsidiary, has been pursuing a listing on the NASDAQ market in the United States, subject to approval of a reverse merger transaction by the China Securities Regulatory Commission ("CSRC"). The Group had expected the review to be completed and the listing to be achieved within the fiscal year ending December 2025. However, as the approval remains pending at this time, the listing gain of JPY 22,854 million that had been included in the profit forecast for the fiscal year ending December 2025 has been excluded. Furthermore, while the initial forecast assumed Cullgen would transition to an equity-method affiliate following its listing, a change in the timing of the listing has resulted in Cullgen remaining a consolidated subsidiary for the second half of the fiscal year. Accordingly, its full-year estimated operating loss of JPY 3,996 million is now reflected in this revised forecast. Impairment Losses: As a result of impairment tests conducted by an independent third-party firm, the recoverable amounts of goodwill related to MICREN Healthcare Co. Ltd., intangible assets related to Shanghai Genomics Technology Ltd., and fixed assets related to Shanghai Rui Fu International Trade Co. Ltd. were determined to be below their carrying amounts, and an impairment loss totaling JPY 468 million is expected to be recognized. Furthermore, with respect to the transaction review related to Cullgen's listing, the approval process remains ongoing. As disclosed on December 19, 2025, the Group is continuing its efforts toward the early realization of the listing while considering alternative options. If the listing is realized in the future, any listing gain will be recognized in the financial results for the accounting period in which the listing occurs; however, the actual amount of such gain will vary depending on the initial public offering price on the listing date as well as foreign exchange movements.공시 • Jan 10GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd.GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd. on December 29, 2025. A cash consideration will be paid by GNI Group Ltd towards common equity of ZOO LABO Co., Ltd. The funds were sourced from the proceeds raised through the overseas public offering conducted in July 2025. GNI Group Ltd. (TSE:2160) completed the acquisition of ZOO LABO Co., Ltd. on December 29, 2025.공시 • Dec 27GNI Group Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026GNI Group Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026공시 • Sep 27GNI Group Ltd. to Report Q3, 2025 Results on Nov 14, 2025GNI Group Ltd. announced that they will report Q3, 2025 results on Nov 14, 2025공시 • Jul 23GNI Group Ltd. has filed a Follow-on Equity Offering.GNI Group Ltd. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 4,000,000공시 • Jun 27GNI Group Ltd. to Report Q2, 2025 Results on Aug 14, 2025GNI Group Ltd. announced that they will report Q2, 2025 results on Aug 14, 2025공시 • Jun 05Gyre Pharmaceuticals Co., Ltd. Announces Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre PharmaceuticalsGNI Group Ltd. announced that its core subsidiary, Gyre Pharmaceuticals Co. Ltd., has commenced sales of "Etorel" (Nintedanib Esilate Soft Capsules), as announced on May 8, 2024, in the press release titled "Notice Regarding License Agreement entered into by GNI's Consolidated Subsidiary, Gyre Pharmaceuticals Co. Ltd., as it has secured the only two approved drugs for pulmonary fibrosis worldwide. This achievement has strategic significance in strengthening its position as a global leading company in the treatment of pulmonary fibrosis, continuously expanding its market share, and enhancing its presence in the field of interstitial lung diseases. The market for pulmonary fibrosis is large, with many unmet clinical needs remaining. Nintedanib Esilates Soft Capsules are approved not only for idiopathic pulmonary fibrosis (IPF), but also for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD). The impact of this development on the company's performance has already been factored into the current consolidated earnings forecast. The impact of this development on The company's performance has already beenfactored into the current consolidated earnings forecasts. The impact of this development On the company's performance has already be factored into the current consolidated Earn forecast. The impact of this develop on the company's performance has also been factored into the current consolidate earnings forecast. The impact of This development on the company's performance have already been factored into the currently consolidated earnings forecast. The impact the development on the company's performance is already been factored into the existing consolidated earnings forecast.공시 • Apr 10GNI Group Ltd. to Report Q1, 2025 Results on May 15, 2025GNI Group Ltd. announced that they will report Q1, 2025 results on May 15, 2025공시 • Feb 18GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2025GNI Group Ltd. provided consolidated earnings guidance for the full year ending December 31, 2025. For the year, the company expects revenue of JPY 28,733 million, operating profit of JPY 23,217 million, profit for the year of JPY 15,868 million and basic earnings per share of JPY 240.42.공시 • Feb 17GNI Group Ltd., Annual General Meeting, Mar 27, 2025GNI Group Ltd., Annual General Meeting, Mar 27, 2025.공시 • Jan 03GNI Group Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025GNI Group Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GNII.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GNII.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장GNI Group 배당 수익률 vs 시장GNII.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GNII.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (GNII.F) (최대 3년)0.6%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GNII.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GNII.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GNII.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GNII.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/03/15 01:24종가2025/12/16 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GNI Group Ltd.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Stephen BarkerJefferies LLCYuriko IshidaMizuho Securities Co., Ltd.null nullStorm Research Limited
공시 • Feb 13GNI Group Ltd., Annual General Meeting, Mar 26, 2026GNI Group Ltd., Annual General Meeting, Mar 26, 2026.
공시 • Jan 23+ 1 more updateGNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2025GNI Group Ltd. revised consolidated earnings guidance for the fiscal year ending December 31, 2025. For the year, the group now expects Revenue of JPY 26,841 million against previous guidance of JPY 28,733 million, operating loss of JPY 2,725 million against previous guidance of operating profit of JPY 23,217 million, Loss Before Income Taxes of JPY 3,795 million against previous guidance of Profit Before Income Taxes of JPY 22,541 million, Loss attributable to the owners of parent of JPY 3,420 million against previous guidance of profit Attributable to Owners of the Parent of JPY 12,058 million, basic loss per share of JPY 65.18 against previous guidance of basic earnings per share of JPY 240.42. Reasons for Revision: Revenue has been revised primarily due to the pharmaceutical business, as Etorel® (nintedanib), which was launched in 2025, is now expected to fall below the initial budget. Meanwhile, in the pharmaceutical business as a whole, sales of the Company's core product, ETUARY®, continue to perform steadily, and revenue is expected to reach a record high for the 12th consecutive fiscal year since its launch in 2014. In addition, in the Medtech business, following the acquisition of Berkeley Advanced Biomaterials (BAB) in 2017, revenue is expected to reach record highs for the 9th consecutive fiscal year. As a result, consolidated revenue is expected to increase by JPY 3,230 million compared to the previous fiscal year, to JPY 26,841 million. Profit: Deferral of the listing of consolidated subsidiary Cullgen. In the Group's pharmaceutical (Biotech) business, Cullgen Inc. ("Cullgen"), a core subsidiary, has been pursuing a listing on the NASDAQ market in the United States, subject to approval of a reverse merger transaction by the China Securities Regulatory Commission ("CSRC"). The Group had expected the review to be completed and the listing to be achieved within the fiscal year ending December 2025. However, as the approval remains pending at this time, the listing gain of JPY 22,854 million that had been included in the profit forecast for the fiscal year ending December 2025 has been excluded. Furthermore, while the initial forecast assumed Cullgen would transition to an equity-method affiliate following its listing, a change in the timing of the listing has resulted in Cullgen remaining a consolidated subsidiary for the second half of the fiscal year. Accordingly, its full-year estimated operating loss of JPY 3,996 million is now reflected in this revised forecast. Impairment Losses: As a result of impairment tests conducted by an independent third-party firm, the recoverable amounts of goodwill related to MICREN Healthcare Co. Ltd., intangible assets related to Shanghai Genomics Technology Ltd., and fixed assets related to Shanghai Rui Fu International Trade Co. Ltd. were determined to be below their carrying amounts, and an impairment loss totaling JPY 468 million is expected to be recognized. Furthermore, with respect to the transaction review related to Cullgen's listing, the approval process remains ongoing. As disclosed on December 19, 2025, the Group is continuing its efforts toward the early realization of the listing while considering alternative options. If the listing is realized in the future, any listing gain will be recognized in the financial results for the accounting period in which the listing occurs; however, the actual amount of such gain will vary depending on the initial public offering price on the listing date as well as foreign exchange movements.
공시 • Jan 10GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd.GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd. on December 29, 2025. A cash consideration will be paid by GNI Group Ltd towards common equity of ZOO LABO Co., Ltd. The funds were sourced from the proceeds raised through the overseas public offering conducted in July 2025. GNI Group Ltd. (TSE:2160) completed the acquisition of ZOO LABO Co., Ltd. on December 29, 2025.
공시 • Dec 27GNI Group Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026GNI Group Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
공시 • Sep 27GNI Group Ltd. to Report Q3, 2025 Results on Nov 14, 2025GNI Group Ltd. announced that they will report Q3, 2025 results on Nov 14, 2025
공시 • Jul 23GNI Group Ltd. has filed a Follow-on Equity Offering.GNI Group Ltd. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 4,000,000
공시 • Jun 27GNI Group Ltd. to Report Q2, 2025 Results on Aug 14, 2025GNI Group Ltd. announced that they will report Q2, 2025 results on Aug 14, 2025
공시 • Jun 05Gyre Pharmaceuticals Co., Ltd. Announces Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre PharmaceuticalsGNI Group Ltd. announced that its core subsidiary, Gyre Pharmaceuticals Co. Ltd., has commenced sales of "Etorel" (Nintedanib Esilate Soft Capsules), as announced on May 8, 2024, in the press release titled "Notice Regarding License Agreement entered into by GNI's Consolidated Subsidiary, Gyre Pharmaceuticals Co. Ltd., as it has secured the only two approved drugs for pulmonary fibrosis worldwide. This achievement has strategic significance in strengthening its position as a global leading company in the treatment of pulmonary fibrosis, continuously expanding its market share, and enhancing its presence in the field of interstitial lung diseases. The market for pulmonary fibrosis is large, with many unmet clinical needs remaining. Nintedanib Esilates Soft Capsules are approved not only for idiopathic pulmonary fibrosis (IPF), but also for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD). The impact of this development on the company's performance has already been factored into the current consolidated earnings forecast. The impact of this development on The company's performance has already beenfactored into the current consolidated earnings forecasts. The impact of this development On the company's performance has already be factored into the current consolidated Earn forecast. The impact of this develop on the company's performance has also been factored into the current consolidate earnings forecast. The impact of This development on the company's performance have already been factored into the currently consolidated earnings forecast. The impact the development on the company's performance is already been factored into the existing consolidated earnings forecast.
공시 • Apr 10GNI Group Ltd. to Report Q1, 2025 Results on May 15, 2025GNI Group Ltd. announced that they will report Q1, 2025 results on May 15, 2025
공시 • Feb 18GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2025GNI Group Ltd. provided consolidated earnings guidance for the full year ending December 31, 2025. For the year, the company expects revenue of JPY 28,733 million, operating profit of JPY 23,217 million, profit for the year of JPY 15,868 million and basic earnings per share of JPY 240.42.
공시 • Feb 17GNI Group Ltd., Annual General Meeting, Mar 27, 2025GNI Group Ltd., Annual General Meeting, Mar 27, 2025.
공시 • Jan 03GNI Group Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025GNI Group Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025